Individuals with schizophrenia show elevated expression of inflammatory markers such as interleukin (IL)-β, IL-6 or C-reactive protein (CRP) in both brain and peripheral blood, thus targeting the neuro-immune system with immune-modulators, anti-inflammatory drugs, antioxidants, nutrients, vitamins, and neuroprotective agents is currently under consideration for the disease management [47-49]. The gene discussed is CRP; the disease is schizophrenia.